We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
+8.53%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$363M
AUM Growth
+$13.2M
Cap. Flow
+$3.91M
Cap. Flow %
1.08%
Top 10 Hldgs %
35.6%
Holding
94
New
25
Increased
21
Reduced
19
Closed
23

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$13.4M
2
BIIB icon
Biogen
BIIB
+$10.6M
3
UHS icon
Universal Health Services
UHS
+$9.83M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$9.37M
5
SNY icon
Sanofi
SNY
+$9.13M

Top Sells

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$10.9M
2
CRL icon
Charles River Laboratories
CRL
+$10.1M
3
MCK icon
McKesson
MCK
+$9.75M
4
CNC icon
Centene
CNC
+$9.59M
5
NVST icon
Envista
NVST
+$7.16M

Sector Composition

Rank Sector Weight
1 Healthcare 93.34%
2 Energy 2.32%
3 Industrials 1.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
26
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$5.94M 1.64%
42,000
-2,000
-5% -$226K
A icon
27
Agilent Technologies
A
$42B
$5.91M 1.63%
+40,000
New +$5.46M
ZBH icon
28
Zimmer Biomet
ZBH
$18.7B
$5.63M 1.55%
36,050
-20,600
-36% -$3.34M
ACCD
29
DELISTED
Accolade Inc
ACCD
$5.43M 1.5%
100,000
+25,000
+33% +$1.21M
NTLA icon
30
Intellia Therapeutics
NTLA
$1.68B
$4.86M 1.34%
30,000
-140,000
-82% -$10.9M
PTCT icon
31
PTC Therapeutics
PTCT
$6.23B
$4.65M 1.28%
110,100
+10,000
+10% +$428K
FOLD
32
DELISTED
Amicus Therapeutics
FOLD
$4.58M 1.26%
+475,000
New +$4.64M
ZLAB icon
33
Zai Lab
ZLAB
$2.65B
$4.42M 1.22%
25,000
-20,000
-44% -$3.22M
RLAY icon
34
Relay Therapeutics
RLAY
$4.37B
$4.39M 1.21%
120,000
+60,000
+100% +$1.98M
ALNY icon
35
Alnylam Pharmaceuticals
ALNY
$29B
$4.24M 1.17%
25,000
-15,000
-38% -$2.2M
AGL icon
36
Agilon Health
AGL
$1.63B
$4.06M 1.12%
+4,000
New +$3.5M
DHR icon
37
Danaher
DHR
$147B
$4.03M 1.11%
16,920
-28,200
-63% -$6.25M
BNTX icon
38
BioNTech
BNTX
$23.3B
$3.81M 1.05%
+17,000
New +$3.21M
PNTG icon
39
Pennant Group
PNTG
$1.38B
$3.68M 1.01%
90,000
+10,000
+13% +$389K
ALKS icon
40
Alkermes
ALKS
$8.29B
$3.68M 1.01%
+150,000
New +$3.34M
REPL icon
41
Replimune Group
REPL
$1.15B
$3.46M 0.95%
90,000
+19,000
+27% +$650K
IRTC icon
42
iRhythm Holdings
IRTC
$4.1B
$3.32M 0.91%
+50,000
New +$3.96M
ACRS icon
43
Aclaris Therapeutics
ACRS
$867M
$3.07M 0.85%
+175,000
New +$3.98M
SIBN icon
44
SI-BONE Inc
SIBN
$844M
$2.83M 0.78%
+90,000
New +$2.91M
AXNX
45
DELISTED
Axonics, Inc. Common Stock
AXNX
$2.54M 0.7%
40,000
– –
CCXI
46
DELISTED
ChemoCentryx, Inc.
CCXI
$2.34M 0.65%
175,000
+20,000
+13% +$493K
APLS
47
DELISTED
Apellis Pharmaceuticals
APLS
$2.21M 0.61%
+35,000
New +$1.81M
AVTX icon
48
Avalo Therapeutics
AVTX
$1.06B
$2.21M 0.61%
234
+26
+13% +$218K
DTIL icon
49
Precision BioSciences
DTIL
$206M
$2.19M 0.6%
+5,833
New +$1.75M
AKRO
50
DELISTED
Akero Therapeutics
AKRO
$2.11M 0.58%
85,000
– –
1
2
3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return
AG
Avala Global New York $2.08B AUM 87.66% 1-Year Est. Return

Integral Health Asset Management's Q2 2021 Portfolio in Review

As of Q2 2021, Integral Health Asset Management held 94 positions worth $363M, up 3.8% from $350M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Integral Health Asset Management's Q2 2021 filing shows 25 new, 21 increased, 19 reduced and 23 closed positions. Its largest new stake was Biogen: 35,000 shares worth $12.1M. The largest sale was Intellia Therapeutics, an estimated $10.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Energy and Industrials.

  • Integral Health Asset Management's largest Q2 2021 buy was Biogen: 35,000 shares worth $12.1M.
  • Integral Health Asset Management added most to Elevance Health in Q2 2021, an estimated $13.4M increase.
  • Integral Health Asset Management's biggest Q2 2021 reduction was Intellia Therapeutics, cutting an estimated $10.9M.
  • Integral Health Asset Management fully exited Charles River Laboratories in Q2 2021, selling an estimated $10.1M.
  • Integral Health Asset Management's ten largest holdings make up 36% of its $363M portfolio in Q2 2021.
  • Integral Health Asset Management opened 25 new positions and closed 23 in Q2 2021.
  • Integral Health Asset Management's portfolio value rose 3.8% quarter-over-quarter to $363M.

Based on Integral Health Asset Management's 13F filing for Q2 2021, filed 13 Aug 2021.